Why semaglutide isn't working the way you expected

The biggest misconception: that a lack of fast results means treatment has failed

A question our prescribers hear most weeks goes roughly like this: "I've been on Wegovy for six weeks and the scales have barely moved — is it even working?" The honest answer is that six weeks on a starter or low dose is not a fair test of semaglutide. The time it takes Wegovy to produce noticeable weight loss is longer than most people expect, because the medicine's job in those early months isn't primarily to drive the number down, it's to let your body adjust to each dose safely.

Treatment starts at 0.25 mg, a level chosen to reduce side effects rather than suppress appetite in a meaningful way. The titration ladder moves through 0.5 mg, 1.0 mg, 1.7 mg and finally 2.4 mg, each step held for around four weeks. For many people, noticeable appetite change only kicks in somewhere between 1.0 mg and 2.4 mg. If you're measuring results at week four on 0.25 mg, you are measuring the wrong thing. The STEP 1 trial, published in the New England Journal of Medicine, recorded an average body-weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose, a timeframe that puts early slow progress in perspective.

That doesn't mean slow progress is always about patience. But the first question a clinician asks is: what dose are you currently on, and how long have you been there?

What actually drives results, and where the gaps often appear

Semaglutide reduces appetite and slows gastric emptying; it doesn't override the physiological effects of too little sleep, very high stress, or a diet that has quietly shifted back towards processed carbohydrates. These aren't failures of willpower. They're variables that blunt the medicine's effect in ways that blood tests and scales can't easily show.

Protein intake matters more than many people realise. When appetite falls sharply, the path of least resistance is to eat less of everything, including protein. That pattern accelerates muscle loss, which lowers your resting metabolic rate and can stall the scales even when total calories are lower. The NHS patient information for semaglutide underlines that treatment is intended alongside a reduced-calorie diet and increased physical activity, the medicine works with those changes, not instead of them.

Timing of injections, consistent injection technique and correct storage also play a role. Semaglutide must be refrigerated; a pen that's spent time out of the cold or been accidentally frozen may be degraded. If your pen feels different or your side effects have suddenly disappeared, that's worth raising with your prescriber. If you're wondering whether your specific experience at a given dose is typical, the broader picture of why semaglutide may not be working covers these practical factors in more detail.

When slow progress points to something worth investigating clinically

There are circumstances where lack of progress isn't explained by dose timing or lifestyle factors. Undiagnosed or undertreated hypothyroidism can significantly limit weight loss on any medicine. Polycystic ovary syndrome (PCOS), insulin resistance and certain medications including corticosteroids, some antidepressants and antipsychotics can all reduce the response to semaglutide. None of these rules out treatment, but they do mean the clinical picture needs reviewing rather than simply waiting longer.

NICE's recommendation for semaglutide (TA875) includes a review point: if you haven't achieved at least 5% weight loss after six months at your maintenance dose, your prescriber should discuss whether continuing makes sense. That's a formal clinical checkpoint, not an arbitrary target. It exists to ensure you're getting genuine benefit, and if you're not, to explore why. You can read more about how Wegovy specifically may not be working for you and what a clinical review typically covers.

If you're getting close to that six-month mark on 2.4 mg and the results aren't there, this is the right moment to speak to a prescriber rather than continue unchanged. Treatment decisions (including whether to continue, switch or investigate further) belong to the clinical conversation, not a self-diagnosis. If you've been considering your options, looking at how long people typically stay on Wegovy may also be useful context. For a full picture of what semaglutide treatment involves, the Wegovy overview covers eligibility, the evidence and what the process looks like.

On the cost side: if you're already on treatment and wondering whether switching provider might affect your results, it's worth understanding what UK Wegovy pricing actually includes and where cheap listings cut corners. Continuity of clinical oversight matters most when treatment isn't going to plan. When you're ready to discuss your progress with a clinician, speaking to our prescribers is the straightforward next step.